<DOC>
	<DOCNO>NCT02913469</DOCNO>
	<brief_summary>Percutaneous coronary intervention ( PCI ) become first choice STEMI patients.According current guideline , dual antiplatelet therapy P2Y12 receptor inhibitor aspirin , intravenous injection morphine therapy chest pain relief necessity play pivotal role treatment patient ST elevation myocardial infarction primary percutaneous coronary intervention.And ticagrelor recommend patient ST segment elevation myocardial infarction undergo PCI , class IB indication.Therefore coadministration morphine ticagrelor commonplace.Currently , study find morphine delay attenuated exposure ticagrelor , clear pathogenesis it.Some researcher say morphine result weaker retarded antiplatelet effect ticagrelor STEMI patient PCI inhibition gastrointestinal peristalsis cause vomiting.The study aim explore whether morphine delay attenuate exposure ticagrelor antiplatelet effect.In addition , trial explore possible mechanism morphne delay attenuate exposure ticagrelor patient ST-segment elevation myocardial infarction PCI .</brief_summary>
	<brief_title>Effects Morphine Loading-dose Ticagrelor Patients With ST-segment Elevation Myocardial Infarction</brief_title>
	<detailed_description>The study single center , randomize , single-blind , control trial.From September 1st , 2014 February 10 , 2016，patients STEMI prepare accept PCI screen accord inclusion criterion . All patient eligibility study receive orally 300 mg load dose ( LD ) plain aspirin 180mg load dose ( LD ) plain ticagrelor sign write informed consent participate study.Then , patient randomly assign four treatment groups.The patient group A would administrate intravenous morphine 5mg metoclopramide 10mg , patient group B would administrate intravenous morphine 5mg 0.9 % normal saline 2ml , patient group C would administrate intravenous metoclopramide 10mg 0.9 % normal saline 2ml , patient group D would administrate intravenous 0.9 % normal saline 2mland 0.9 % normal saline 2ml . Subsequently，all patient would receive orally plain aspirin 100mg day plain ticagrelor 90mg twice day 1 month follow-up.The investigator would calculate platelet response index LD 0.5h,2h,8h LD platelet vasodilator-stimulated phosphoprotein phosphorylation assay flow cytometry instrument ( BD FACS Calibur ) . The primary study end-point platelet response index PRI VASP 2 hour LD . Secondary end-points ( 1 ) The platelet response index PRI VASP half hour 8 hour LD . ( 2 ) Record electrocardiogram change ( incidence 70 % reduction PCI , TIMI flow crime vessel ( TIMI flow frame ) , incidence acute/subacute thrombotic event , incidence major adverse cardiovascular cerebrovascular event , incidence primary secondary bleeding .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior studyspecific procedure 2 . Male female age 18 80 year old 3 . Patients STEMI schedule undergo PCI . 1 . Hypersensitivity active substance excipients 2 . Active bleed bleed diathesis 3 . Previous transient ischemic attack 4 . Antiplatelet ( clopidogrel , prasugrel , ticagrelor ) administration week index event 5 . Known relevant hematological condition 6 . Left ventricular ejection fraction ≤ 30 % 7 . Renal failure creatinine ≥ 3 mg/dl 8 . History liver disease 9 . Increased risk bradycardia 10 . Concomitant therapy drug know interfere CYP3A4 metabolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Morphine，Ticagrelor，STEMI，PCI</keyword>
</DOC>